思考与建议:“ENVACAR”商标驳回复审案中的程序问题

Reflection and Recommendation:Procedural Issues in the Case of Reexamination of Rejection of ENVACAR Trademark

申请人-美国辉瑞产品有限公司於2001年9月3日在第5类“医药制剂、人用药、兽医用制剂”商品上，向国家工商行政管理局商标局（下称“商标局”）提出注册英文文字商标“ENVACAR”的申请。2002年10月10日商标局以“该商标译为硫酸胍生。是一抗高血压药的通用名称，不能作为商标”为理由予以驳回。

On 3 September 2001, the applicant, the US Pfizer Products Inc., filed an application with the Trademark Office of the State Administration for Industry and Commerce （the Trademark Office for short） for registration of the English trademark “ENVACAR” in the goods of class 5 “preparations for pharmaceutical purposes, medicines for human purposes, and veterinary preparations”. On 10 October 2002, the Trademark Office rejected the application on the ground that“the trademark, translated into Chinese, is the generic name of Guanoxan Sulfate, which is an anti-highblood-pressure medicine.